


Brain Tech TIME

(Teaching Imaging and Multidisciplinary Education)



I-123 Ioflupane

1. INDICATIONS:

Indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using SPECT imaging for the evaluation of adult patients with suspected Parkinsonian syndromes or suspected dementia with Lewey Bodies.

2. CONTRAINDICATIONS:

- Known hypersensitivity to the active substance or to any of its excipients. An iodine allergy is not a contraindication to receiving the tracer.
- Inability to cooperate with SPECT or SPECT/CT brain imaging.
- ^{123}I -ioflupane imaging should be performed on a pregnant woman only if there is a clear clinical benefit.

3. ADVERSE REACTIONS:

In clinical trials, the most common adverse reactions; headache, nausea, vertigo, dry mouth, and dizziness, occurred in <1% of subjects.

4. SUPPLIED AND STORAGE:

- Supplied in 10 ml glass vials containing a total volume of 2.5 ml of solution with a total radioactivity of 185 MBq (5 mCi) at calibration time.
- Store ^{123}I -ioflupane at 20° to 25° C (68° to 77°), within the original lead container or equivalent.
- Does not contain a preservative.
- Do not use ^{123}I -ioflupane preparations after the expiration date and time stated on the label.

5. PATIENT PREPARATION:

- Check medications that may alter tracer binding, and (if possible) stop such medications for at least 5 half-lives.
- To reduce exposure to the thyroid, administer a potassium iodide oral solution or strong iodide solution (e.g. Lugol's solution) equivalent to 100 mg of iodine at least 1 hour prior to injection.
- Avoid the use of these products in patients with known sensitivities.

6. DOSE AND ADMINISTRATION:

- 111 to 185 MBq (3 to 5 mCi) ^{123}I -ioflupane (DaTscan™ or generic) administered intravenously.
- Inspect the radiopharmaceutical dose solution prior to administration and do not use it if it contains particulate material or is discolored.

7. IMAGING PARAMETERS:

- SPECT imaging should be started between 3 and 6 hours after injection using a gamma camera fitted with high-resolution collimators.
- Keep the patient supine (head in) with the head positioned to center the brain in the scanner field of view. Reduce head movement with tape or other flexible head restraints if necessary.

8. PATIENT INSTRUCTION:

- Advise patient to hydrate and void after procedure for 48 hours after tracer administration to reduce radiation exposure if possible.
- Inform patients who are breastfeeding to use alternate infant nutrition sources (e.g. stored breast milk or infant formula) for 6 days after administration of the drug.

Funding for the Brain Tech TIME initiative was provided by Lilly.